Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function

Jason N Barreto, Allison L McClanahan, Andrew D Rule, Carrie A Thompson, Erin Frazee, Jason N Barreto, Allison L McClanahan, Andrew D Rule, Carrie A Thompson, Erin Frazee

Abstract

High-dose methotrexate (MTX; ≥1 g/m2) is a renally eliminated and nephrotoxic first-line therapy for central nervous system (CNS) lymphoma. Creatinine-based estimation of renal function is the recommended approach to dosing MTX in these cases, but nonrenal determinants of creatinine production and elimination in cancer patients such as malnutrition and cachexia lead to overestimation of glomerular filtration rate (GFR) by this method and a heightened risk for drug toxicity. Serum cystatin C is one of the first readily available, relatively inexpensive, endogenous biomarkers to emerge as a practical adjunct to creatinine for estimation of renal function for drug dosing. In this report, we describe two cases where cystatin C was used in conjunction with creatinine to inform MTX dosing for CNS lymphoma. In both cases, the estimated GFR was nearly 40% lower with the combination of the two biomarkers compared to creatinine-only estimates. Empiric MTX dose reductions as a product of these results likely spared the patients sustained exposure to toxic drug concentrations and facilitated earlier administration of supportive care interventions. Further prospective investigations with validated dosing regimens including cystatin C are warranted for high-dose MTX.

References

    1. Rubenstein J. L., Gupta N. K., Mannis G. N., LaMarre A. K., Treseler P. How I treat CNS lymphomas. Blood. 2013;122(14):2318–2330. doi: 10.1182/blood-2013-06-453084.
    1. Dalia S., Price S., Forsyth P., Sokol L., Jaglal M. What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma? Leukemia & Lymphoma. 2015;56(2):500–502. doi: 10.3109/10428194.2014.927458.
    1. Perazella M. A., Moeckel G. W. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Seminars in Nephrology. 2010;30(6):570–581. doi: 10.1016/j.semnephrol.2010.09.005.
    1. Howard S. C., McCormick J., Pui C. H., Buddington R. K., Harvey R. D. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482. doi: 10.1634/theoncologist.2015-0164.
    1. Pinedo H. M., Chabner B. A. Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treatment Reports. 1977;61:709–715.
    1. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580.
    1. Batchelor T., Carson K., O’Neill A., et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. Journal of Clinical Oncology. 2003;21(6):1044–1049. doi: 10.1200/jco.2003.03.036.
    1. Lameire N., Van Biesen W., Vanholder R. Acute renal problems in the critically ill cancer patient. Current Opinion in Critical Care. 2008;14(6):635–646. doi: 10.1097/mcc.0b013e32830ef70b.
    1. Zhu J.-J., Gerstner E. R., Engler D. A., et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro-Oncology. 2009;11(2):211–215. doi: 10.1215/15228517-2008-067.
    1. Nirenberg A., Mosende C., Mehta B. M., et al. High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treatment Reports. 1977;61:779–783.
    1. Gerstner E. R., Carson K. A., Grossman S. A., Batchelor T. T. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology. 2008;70(5):401–402. doi: 10.1212/01.wnl.0000300671.37279.0e.
    1. Gerber D. E., Grossman S. A., Batchelor T., Ye X. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. Cancer Chemotherapy and Pharmacology. 2007;59(6):817–823. doi: 10.1007/s00280-006-0339-x.
    1. Matzke G. R., Aronoff G. R., Atkinson A. J., et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney International. 2011;80(11):1122–1137. doi: 10.1038/ki.2011.322.
    1. Mussap M., Plebani M. Biochemistry and clinical role of human cystatin C. Critical Reviews in Clinical Laboratory Sciences. 2004;41(5):467–550. doi: 10.1080/10408360490504934.
    1. Stevens L. A., Schmid C. H., Greene T., et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney International. 2009;75(6):652–660. doi: 10.1038/ki.2008.638.
    1. Segarra A., de la Torre J., Ramos N., et al. Assessing glomerular filtration rate in hospitalized patients: a comparison between CKD-EPI and four cystatin C-based equations. Clinical Journal of the American Society of Nephrology. 2011;6(10):2411–2420. doi: 10.2215/cjn.01150211.
    1. Chew-Harris J. S., Florkowski C. M., George P. M., Elmslie J. L., Endre Z. H. The relative effects of fat versus muscle mass on cystatin C and estimates of renal function in healthy young men. Annals of Clinical Biochemistry. 2013;50(1):39–46. doi: 10.1258/acb.2012.011241.
    1. Tenstad O., Roald A. B., Grubb A., Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scandinavian Journal of Clinical and Laboratory Investigation. 1996;56(5):409–414. doi: 10.3109/00365519609088795.
    1. Mulaomerović A., Halilbašić A., Čičkušić E., Zavašnik-Bergant T., Begić L., Kos J. Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma. Cancer Letters. 2007;248(2):192–197. doi: 10.1016/j.canlet.2006.07.004.
    1. Softic A., Begic L., Halilbasic A., Vižin T., Kos J. The predictive value of cystatin C in monitoring of B non-hodgkin lymphomas: relation to biochemical and clinical parameters. ISRN Oncology. 2013;2013:6. doi: 10.1155/2013/752792.752792
    1. Hammouda N. E., Salah El-Din M. A., El-Shishtawy M. M., El-Gayar A. M. Serum cystatin C as a biomarker in diffuse large B-cell lymphoma. Scientia Pharmaceutica. 2017;85(4):p. 9. doi: 10.3390/scipharm85010009.
    1. Ylinen E., Jahnukainen K., Saarinen-Pihkala U. M., Jahnukainen T. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia. Pediatric Blood & Cancer. 2014;61(12):2199–2202. doi: 10.1002/pbc.25137.
    1. Stoller R. G., Hande K. R., Jacobs S. A., et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New England Journal of Medicine. 1977;297(12):630–634. doi: 10.1056/nejm197709222971203.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere